| Frederick Gerald Wasserman |
Frederick Gerald Wasserman is a businessperson who has been at the head of 7 different companies and presently is Non-Executive Chairman for DLH Holdings Corp., Chairman at Marker Therapeutics, Inc. and President of FGW Partners LLC.
In the past he held the position of President, Chief Operating & Financial Officer at Mitchell & Ness Nostalgia Co., Senior Vice President-Finance & Administration at Score Board, Inc., Chairman of MAM Software Group, Inc., President & Chief Financial Officer of Papel Giftware, Inc., President & Chief Financial Officer of Goebel of North America and Chief Compliance Officer of Wynnefield Capital Management LLC.
Mr. Wasserman received an undergraduate degree from The Wharton School of the University of Pennsylvania. |
| Monic Stuart |
Dr. Monic Stuart, MD, is a Chief Medical Officer at Marker Therapeutics, Inc. Dr. Stuart was previously employed as a Vice President-Clinical Development by Geron Corp. and a Senior Medical Director by Genentech, Inc. He received his undergraduate degree from the University of North Carolina at Chapel Hill, a graduate degree from The Johns Hopkins University and a doctorate degree from the University of North Carolina at Chapel Hill. |
| Gerald Garrett |
Gerald Garrett is currently the Vice President-Clinical Operations at Marker Therapeutics, Inc. He obtained his undergraduate degree from Texas A&M University. |
| Mythili Koneru |
Mythili Koneru is Chief Medical Officer at Marker Therapeutics, Inc.
In the past she occupied the position of Associate Vice President-Immuno-Oncology at Eli Lilly & Co.
She received an undergraduate degree from The University of Chicago, a doctorate from New York University and a doctorate from Robert Wood Johnson Medical School. |
| Anthony H. Kim |
Currently, Anthony H. Kim holds the position of Chief Financial Officer at Marker Therapeutics, Inc.
In the past Mr. Kim was Vice President-Health Group at Houlihan Lokey, Inc., Senior Vice President-Healthcare Group at Jefferies LLC and Executive Director-Healthcare Group at Nomura Securities International, Inc.
Mr. Kim received an undergraduate degree from The University of Chicago and an MBA from UCLA Anderson School of Management. |
| Tsvetelina Pencheva Hoang |
Dr. Tsvetelina P. Hoang is a Vice President-Research & Development at Marker Therapeutics, Inc. Dr. Hoang was previously employed as a Director-Translational Research by Bellicum Pharmaceuticals, Inc. and a Member by The Phi Beta Kappa Society. She received her undergraduate degree from Yale University, a graduate degree from Yale University and a doctorate degree from The Johns Hopkins University. |
| Patricia Allison |
Patricia Allison currently works as the Head of Clinical Operations at Marker Therapeutics, Inc. |
| Michael J. Loiacono |
Michael J. Loiacono is Secretary, Treasurer & Chief Accounting Officer at Marker Therapeutics, Inc.
Mr. Loiacono previously was Chief Financial & Accounting Officer for Global Axcess Corp., CFO, CAO & Investor Relations Contact at Global Axcess Corp., Vice President-Finance of Reach Services (USA), Inc., Controller & Finance Director at ITXC Corp., Vice President-Finance for InfiniRoute Networks, Inc., Head-Strategic Development at Fiduciary Trust Company International (13906) and Head-Strategic Development at FCTI, Inc.
He received an undergraduate degree from Rutgers Business School. |
| Eliot M. Lurier |
Eliot M. Lurier holds the position of Chief Financial Officer at Tenax Therapeutics, Inc., Chief Financial Officer at Marker Therapeutics, Inc., Chief Financial Officer of Mustang Bio, Inc. and Chief Financial & Accounting Officer for SomaLogic, Inc.
In his past career he held the position of Chief Financial Officer of Admetric Biochem, Inc., Chief Financial Officer of Danforth Advisors LLC, Chief Operating & Financial Officer at Bridge Pharmaceuticals, Inc., Chief Financial Officer, Treasurer & VP at BioMarin Pediatrics II, Inc., CFO, Treasurer & Head-Investor Relations at Interleukin Genetics, Inc., Chief Financial Officer & VP-Administration at NUCRYST Pharmaceuticals Corp., Auditor for Coopers & Lybrand Sp zoo and Chief Financial Officer of Joslin Diabetes Center, Inc.
Eliot M. Lurier received an undergraduate degree from Syracuse University. |
| Peter L. Hoang |
Peter L. Hoang occupies the position of President, Chief Executive Officer & Director at Marker Therapeutics, Inc. He is also on the board of Esperance Pharmaceuticals, Inc.
In his past career he held the position of President & Chief Executive Officer for Tapimmune, Inc., Head-Mergers & Acquisitions at JPMorgan Chase & Co., Senior VP-Business Development & Strategy at Bellicum Pharmaceuticals, Inc., MD, Head-Healthcare Mergers & Acquisitions at CIT Group, Inc., Executive Director-Global Mergers & Acquisitions at Oppenheimer & Co., Inc., Head-Mergers & Acquisitions at Deutsche Bank Corp., Head-Mergers & Acquisitions at Merrill Lynch & Co., Inc. and Managing Director-Innovations at The University of Texas M.D. Anderson Cancer Center.
Mr. Hoang received an undergraduate degree from Yale University and an MBA from UCLA Anderson School of Management. |
| Juan F. Vera |
Dr. Juan F. Vera, MD, is a President, CEO, CFO, Chief Accounting Officer at Marker Therapeutics, Inc. and an Associate Professor at Baylor College of Medicine. He is on the Board of Directors at Marker Therapeutics, Inc. and AlloVir, Inc. Dr. Vera was previously employed as a Founder by Marker Cell Therapy, Inc. He received his doctorate degree from Universidad El Bosque. |
| Norman David Eansor |
Mr. Norman D. Eansor is an Independent Chairman at Marker Therapeutics, Inc. and a President at Cyvek, Inc. He is on the Board of Directors at B-MoGen Biotechnologies, Inc. Mr. Eansor was previously employed as a President-Protein Sciences Segment by Bio-Techne Corp., a Senior Vice President-Development & MD by Novus Biologicals LLC, a President-Bioproducts Business Unit by Cambrex Corp., a President-Bioscience Division by Thermo Fisher Scientific, Inc., a Vice President-Operations by Cardinal Health Corp., and a Vice President-Pharmaceutical Operations by R.P. Scherer Corp. He received his undergraduate degree from the University of Western Ontario and an MBA from the University of Windsor. |
| John R. Wilson |
Mr. John R. Wilson is a Chief Executive Officer at Wilson Wolf Manufacturing Corp. and an Independent Director at Marker Therapeutics, Inc. He is on the Board of Directors at Marker Therapeutics, Inc. Mr. Wilson was previously employed as an Independent Non-Executive Director by AlloVir, Inc., a Principal by Cellex Biosciences, Inc., and a Chief Executive Officer by Marker Cell Therapy, Inc. He received his undergraduate degree from Hamline University and an undergraduate degree from the University of Minnesota. |
| Katharine Knobil |
Dr. Katharine Knobil, MD, is an Independent Director at Pliant Therapeutics, Inc., an Independent Director at Marker Therapeutics, Inc. and a Member at The National Academies of Science. She is on the Board of Directors at Pliant Therapeutics, Inc., Marker Therapeutics, Inc. and Nimbus Therapeutics LLC. Dr. Knobil was previously employed as a Chief Medical Officer by Agilent Technologies, Inc., an Independent Director by Arena Pharmaceuticals, Inc., a Chief Medical Officer, Head-Research & Development by Kaleido Biosciences, Inc., and a Chief Medical Officer & Senior Vice President by GlaxoSmithKline LLC. She also served on the board at The National Health Council and Patient-Centered Outcomes Research Institute. She received her undergraduate degree from Cornell University and a doctorate degree from The University of Texas Southwestern Medical Center. |
| Steven Arnote Elms |
Steven Arnote Elms is currently the Chairman at ADMA Biologics, Inc. and Elevation Oncology, Inc. He is also an Independent Director at Marker Therapeutics, Inc. and a Director at Marker Cell Therapy, Inc. Additionally, he serves as a Director at Ajax Health LLC, Ajax Health II LLC, and Treeline Biosciences, Inc. Mr. Elms previously held positions as Chairman at MAP Pharmaceuticals LLC, Adams Respiratory Therapeutics, Inc., and Oculex Pharmaceuticals, Inc. He was also a Co-Chairman at LENSAR, Inc. and served as a Director at Bioenvision, Inc., Advion BioSciences, Inc., Avera Pharmaceuticals, Inc., Ambit Biosciences Corp., TRIA Beauty, Inc., CeNeRx BioPharma, Inc., NextWave Pharmaceuticals, Inc., Earlens Corp., Advion, Inc., Novazyme Pharmaceuticals, Inc., Medical Knowledge Group LLC, Scerene Healthcare, Inc., and Archimica Cooperatief UA. Additionally, he was an Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc. and Zosano Pharma Corp. Mr. Elms also served as an Independent Director at Loxo Oncology, Inc. and Cidara Therapeutics, Inc. He has a background in business administration, having obtained an MBA from Kellogg School of Management. |
| David Laskow-Pooley |
David Laskow-Pooley is a businessperson who founded Pharmafor Ltd. and who has been the head of 6 different companies. Currently, he occupies the position of Chairman of Abliva AB, Chairman of Oxford Silk Phage Technologies Ltd., Chief Executive Officer & Director at Pharmafor Ltd. and Scientific Advisor at Q BioMed, Inc. He is also on the board of Marker Therapeutics, Inc., Ocean Broadband Networks (Shanghai) Co., Ltd., OBN (UK) Ltd. (former Chairman) and LREsystem Ltd.
Dr. Laskow-Pooley previously was Chief Executive Officer & Director at LondonPharma Ltd., Chief Executive Officer at Surface Therapeutics Ltd. and Managing Director-UK Division at OSI Pharmaceuticals, Inc.
He received an undergraduate degree from the University of Sunderland. |
